Close
CDMO Safety Testing 2026
Novotech

Made Smarter Advances AI in Manufacturing with New Toolkit

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Teva Adds Ecopipam Therapy in $700M Emalex Acquisition Deal

Teva Pharmaceuticals has entered into a definitive agreement to...

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.
- Advertisement -

A new initiative from Made Smarter is aiming to simplify how manufacturers approach artificial intelligence, with a focus on practical deployment rather than theoretical potential. The organisation has introduced a downloadable guide titled AI Adoption in Manufacturing: A Practical Toolkit from Made Smarter, designed specifically to support SME leaders as they navigate the growing relevance of AI in Manufacturing. Developed in collaboration with Chris Dungey, the resource addresses persistent uncertainty among manufacturers around where to begin, how to mitigate risks, and how to translate AI into tangible operational value.

Rather than emphasising complex systems, the toolkit adopts a task-oriented methodology that directs businesses to identify operational inefficiencies and areas where AI can deliver immediate benefits. Central to this is the โ€œScan, Pilot, Scaleโ€ framework, which reflects real-world adoption patterns across the sector. The approach encourages manufacturers to begin with clearly defined challenges, validate solutions in controlled settings, and expand implementation only after measurable success. This structure is particularly relevant in industrial environments where AI deployment intersects with safety, compliance, and productivity requirements, making cautious and structured adoption essential.

The guidance also outlines how AI can be applied across manufacturing processes, including predicting outcomes, identifying operational anomalies, and automating routine activities. It highlights typical barriers faced by SMEs, such as fragmented datasets and limited internal capabilities, while offering a pathway to overcome them. Case studies from companies including D Squared Product Development, Ritherdon & Co., Arden Dies, and ELE Advanced Technologies demonstrate how AI is already being used to optimise design processes, streamline order workflows, improve customer engagement, and monitor equipment performance.

The toolkit has been developed by Made Smarter North West alongside Manufacturing Technology Centre, incorporating insights on workforce readiness and the skills needed to support long-term adoption. Kevin Smith, Lead Technology Adoption Specialist at Made Smarter North West, said: โ€œAI is no longer out of reach for SMEs. It doesnโ€™t require major investment or specialist teams to get started. The opportunity now is to act with confidence and clarity. By starting small, testing safely and focusing on real business value, manufacturers can turn AI from an abstract concept into a practical tool for growth.โ€ As industry momentum builds, the initiative reinforces how AI in Manufacturing can shift from experimentation to structured, scalable implementation.

Latest stories

Related stories

Teva Adds Ecopipam Therapy in $700M Emalex Acquisition Deal

Teva Pharmaceuticals has entered into a definitive agreement to...

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป